In a recently published Law360 article, Banner Witcoff’s Jason Shull discusses the U.S. Supreme Court agreeing to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that sits at the intersection of patent law, U.S. Food and Drug Administration regulation, and generic drug competition.
The article explains Hikma v. Amarin matters now, how it fits within existing inducement doctrine and what practitioners should be thinking about as the case proceeds.
The full article can be found by clicking here.
Posted: February 4, 2026
